New class of synthetic antibiotics set to tackle superbugs

Recce Pharmaceuticals is commercializing a novel synthetic broad-spectrum antibiotic designed to overcome antimicrobial resistance. Its lead compound, RECCE 327, is one of the first entirely new classes of antibiotics to be developed in more than 30 years.

Go to the profile of Recce Pharmaceuticals
Nov 28, 2019
0
0

Download the Full PDF

RECCE 327 developed by Recce Pharmaceuticals Ltd (ASX:RCE) has destroyed every bacterium it has been tested against, including superbugs, and has proved invulnerable to any attempt by bacteria to mutate and overcome its mechanism of action.

The promising new drug is currently in the final preclinical stages with preparations underway for first-in-human clinical trials. Recce’s new compound is a broad-spectrum antibiotic initially to be used intravenously against Escherichia coli and Staphylococcus aureus bacteria in the blood, including superbug forms. In a sign of growing global interest, Australian- based Recce has been awarded qualified infectious disease product (QIDP) designation by the US Food & Drug Administration (FDA).

The QIDP designation, awarded under the Generating Antibiotic Initiatives Now (GAIN) Act, means the antibiotic has fast track designation along with 10 years of market exclusivity post-approval.

“It is a completely new class of broad-spectrum antibiotic that will kill all bacteria, including super-bugs. Even when bacteria attempt to mutate, the antibiotic continues to work,” said VP James Graham. Traditionally, antibiotics have come from natural sources, for instance penicillin, or are modified to achieve broad-spectrum activity. Using a so-called ‘lock and key’ mechanism at the cellular level, these drugs lock into a specific part of the bacterial membrane and attack it. Once the bacteria mutate, the antibiotic is rendered useless.

A universal mechanism

“The antibiotic mechanism is novel, universal and can be considered as the master key,” Graham said. “It locks on to the bacterial membrane, reacts with the protein and kills the bacteria. Its unique action and composition means it can overcome any attempt by bacteria to mutate. There are no signs that its potency lessens, even with repeated use” (Fig. 1).

Based on a patented polymeric structure, Recce’s antibiotic has millions of active sites, compared with only one, two or three active sites of traditional antibiotics.

Recce VP and co-inventor of the technology, Michele Dilizia, said it was widely acknowledged that antimicrobial resistance (AMR) was one of the world’s most urgent unmet medical issues. “Multidrug- resistant bacteria cause the deaths of more than 700,000 people annually, and millions more have serious complications from infections. AMR is forecast to kill up to 10 million people annually by 2050 unless solutions are found,” she said.

As well as their ability to mutate, bacteria can also acquire resistance from other bacteria through gene transfer. Global over-use of antibiotics in agriculture and animal husbandry, as well as over-prescribing, has compounded the problem.

Fig. 1 | The universal mechanism of RECCE 327. The compound binds to the outer membrane of bacteria, interacts with bacterial plasma membrane proteins causing the bacteria to burst

Antibiotic development has stalled

Almost every antibiotic on the market today is based on scientific discoveries made more than 30 years ago. Development of new antibiotics has faltered, owing to a lower return on investment compared with drugs used for long-term chronic conditions. Doctors avoid prescribing new antibiotics for fear they will dilute their potency.

Underscoring the urgent need for new antibiotic solutions, Recce is permitted to supply RECCE 327 to Australian medical practitioners in defined circumstances under the Australian Therapeutic Goods Administration (TGA) Special Access Scheme Category A.

“In the absence of an industry response, a number of forward-looking institutions including governments, medical groups, private enterprise and the World Health Organization are now urgently working to address the growing threat of AMR,” Dilizia said.

“New initiatives include additional support for R&D costs, acceleration of regulatory pathways, extended market exclusivity and the removal of market barriers.” “RECCE 327’s approval for QIDP designation underscored the potential of synthetic polymers as a new class of antibiotics,” said co-inventor, VP and chief research officer, Graham Melrose. “RECCE 327 was developed primarily to address the unmet need globally to treat blood infections and sepsis resulting from E. coli and S. aureus bacteria,” continued Melrose. “Currently there are no antibiotics specifically for treating sepsis, so there is a huge and urgent need for effective, safe treatments.”

The technology can be delivered in various formulations and treat a range of infections; e.g. an oral formulation is planned for Helicobacter pylori bacteria. Melrose said the technology would revolutionize the antibiotic business model. “RECCE 327 will keep on working, despite any bacterial mutations. It will never lose its effectiveness and physicians will have great confidence in prescribing it.”

The American market is strongly in Recce’s sights, as it comprises about 47% of the antibiotic market. Recce will maintain manufacturing operations in Australia.

 Contact:

James Graham, Vice-President
Recce Pharmaceuticals Ltd
Sydney, NSW, Australia
Tel: +61 2 8075 4585
Email: james.graham@recce.com.au
Website: www.recce.com.au


Go to the profile of Recce Pharmaceuticals

Recce Pharmaceuticals

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a New Class of Synthetic Antibiotics with Broad Spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Recce antibiotics are unique – their potency does not diminish even with repeated use, which is a common failure associated with existing antibiotic use and the resulting emergence of resistant superbugs. Patented lead candidate RECCE® 327, wholly owned and manufactured in Australia, has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.

No comments yet.